CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 34 enrolled
Drug / intervention
Vaxchoradrug
Likely dose
Vaxchora 100 mLfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03251495
NCT03251495Phase 2Completed
CompareCT.gov

Immunologic Responses to a Live Attenuated Oral Cholera Vaccine

Emory University·interventional·Posted Aug 16, 2017·Updated Feb 13, 2026

In Brief

A Phase 2 clinical trial evaluating Vaxchora for Cholera. Completed, enrolled 34 participants across 1 site.

Detailed Summary

The primary objective of this study is to evaluate the antibody response to the cholera vaccine, Vaxchora®, in healthy subjects. Investigators also seek to evaluate additional markers of the adaptive immune response including plasmablasts, activated B cells, memory B cells, and T cell responses in healthy subjects receiving cholera vaccine, produce monoclonal antibodies against cholera, and evaluate the safety and reactogenicity in healthy subjects receiving cholera vaccine.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsCholera
CountriesUnited States
CollaboratorsNational Institute of Allergy and Infectious Diseases (NIAID)

Timeline

Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedAug 16, 2017
Enrollment StartAug 29, 2017
Primary CompletionDec 10, 2024
Study CompletionNov 6, 2025
TodayJul 2, 2026
Enrollment to primary: 7.3 yearsPosted 8.9 years ago

Interventions

Vaxchoradrug

Vaxchora is a live attenuated cholera vaccine that provides immunity against V. cholerae serogroup O1. Participants will receive one single oral dose of 100 mL.